Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Schizophrenia is a chronic disabling disease which in the majority of cases requires long-term treatment with antipsychotic medication. Before the development of atypical antipsychotics, treatment choice was restricted to conventional (or typical) antipsychotics, which are known to cause a range of side effects including extrapyramidal symptoms. Although atypical agents provide a favourable alternative (advocated by the National Institute of Clinical Excellence in the UK), they are associated with side effects. These differ between agents, but can include weight gain, sedation and hyperprolactinaemia. Aripiprazole is a newly available atypical antipsychotic for the treatment of schizophrenia. With the apparent imitations of currently available medications, aripiprazole provides clinicians with another treatment option. The purpose of these guidelines is to outline the consensus reached by the Schizophrenia Innovation Working Group on best practice in prescribing and appropriate use of aripiprazole in the UK.

Original publication

DOI

10.1111/j.1368-5031.2005.00498.x

Type

Journal article

Journal

Int J Clin Pract

Publication Date

04/2005

Volume

59

Pages

485 - 495

Keywords

Antipsychotic Agents, Aripiprazole, Consensus, Drug Interactions, Heart Diseases, Humans, Hypertension, Mental Disorders, Metabolic Diseases, Patient Compliance, Piperazines, Quinolones, Schizophrenia, Treatment Outcome